natgillin/translations-raw huggingface dataset:
PegIntron 80 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen (CLEARCLICK) is reconstituted with the solvent provided in the two-chamber cartridge (water for injections) for administration of up to 0.5 ml of solution.
PegIntron 80 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Svaka napunjena brizgalica (CLEARCLICK) rekonstituira se s otapalom (voda za injekcije) koje se nalazi u ulošku s dvije komore, za primjenu najviše 0,5 ml otopine.
PegIntron 100 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen contains 100 micrograms of peginterferon alfa-2b measured on a protein basis.
PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Jedna napunjena brizgalica sadrži 100 mikrograma peginterferona alfa-2b, mjereno na bazi proteina.
PegIntron 100 micrograms powder and solvent for solution for injection Each vial contains 100 micrograms of peginterferon alfa-2b measured on a protein basis.
PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju Jedna bočica sadrži 100 mikrograma peginterferona alfa-2b, mjereno na bazi proteina.
PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen (CLEARCLICK) is reconstituted with the solvent provided in the two-chamber cartridge (water for injections) for administration of up to 0.5 ml of solution.
PegIntron 150 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Svaka napunjena brizgalica (CLEARCLICK) rekonstituira se s otapalom (voda za injekcije) koje se nalazi u ulošku s dvije komore, za primjenu najviše 0,5 ml otopine.
EU/1/00/131/039 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/040 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/042 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/039 (1 brizgalica, 1 igla za injekciju i 2 tupfera za čišćenje) EU/1/00/131/040 (4 brizgalice, 4 igle za injekciju i 8 tupfera za čišćenje) EU/1/00/131/042 (12 brizgalica, 12 igala za injekciju i 24 tupfera za čišćenje)
PegIntron 50 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
PegIntron 50 mikrograma prašak i otapalo za otopinu za injekciju Svaka bočica mora se rekonstituirati sa 0,7 ml vode za injekcije za primjenu najviše 0,5 ml otopine.
PegIntron 120 micrograms powder for injection peginterferon alfa-2b
PegIntron 120 mikrograma prašak za injekciju peginterferon alfa-2b s.c.
PegIntron 80 micrograms powder and solvent for solution for injection Each vial contains 80 micrograms of peginterferon alfa-2b measured on a protein basis.
PegIntron 80 mikrograma prašak i otapalo za otopinu za injekciju Jedna bočica sadrži 80 mikrograma peginterferona alfa-2b, mjereno na bazi proteina.
EU/1/00/131/001 (1 vial of powder, 1 ampoule of solvent) EU/1/00/131/002 (1 vial of powder, 1 ampoule of solvent, 1 injection syringe, 2 injection needles and 1 cleansing swab)
EU/1/00/131/001 (1 bočica s praškom, 1 ampula s otapalom) EU/1/00/131/002 (1 bočica s praškom, 1 ampula s otapalom, 1 štrcaljka za injekciju, 2 igle za injekciju i 1 tupfer za čišćenje)
PegIntron 50 micrograms powder for injection peginterferon alfa-2b
PegIntron 50 mikrograma prašak za injekciju peginterferon alfa-2b s.c.
PegIntron 50 micrograms powder and solvent for solution for injection Each vial contains 50 micrograms of peginterferon alfa-2b measured on a protein basis.
PegIntron 50 mikrograma prašak i otapalo za otopinu za injekciju Jedna bočica sadrži 50 mikrograma peginterferona alfa-2b, mjereno na bazi proteina.
PegIntron 150 micrograms powder and solvent for solution for injection Each vial contains 150 micrograms of peginterferon alfa-2b measured on a protein basis.
PegIntron 150 mikrograma prašak i otapalo za otopinu za injekciju Jedna bočica sadrži 150 mikrograma peginterferona alfa-2b, mjereno na bazi proteina.
EU/1/00/131/003 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/004 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
EU/1/00/131/003 (4 bočice s praškom, 4 ampule s otapalom) EU/1/00/131/004 (4 bočice s praškom, 4 ampule s otapalom, 4 štrcaljke za injekciju, 8 igala za injekciju i 4 tupfera za čišćenje)
PegIntron 120 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen (CLEARCLICK) is reconstituted with the solvent provided in the two-chamber cartridge (water for injections) for administration of up to 0.5 ml of solution.
PegIntron 120 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Svaka napunjena brizgalica (CLEARCLICK) rekonstituira se s otapalom (voda za injekcije) koje se nalazi u ulošku s dvije komore, za primjenu najviše 0,5 ml otopine.
3 was observed in 4 % (8/194) of patients receiving PegIntron in combination with ribavirin.
3 također u 4% (8/194) bolesnika koji su primali
PegIntron 100 micrograms powder for injection peginterferon alfa-2b
PegIntron 100 mikrograma prašak za injekciju peginterferon alfa-2b s.c.
EU/1/00/131/013 (4 vials of powder, 4 ampoules of solvent) EU/1/00/131/014 (4 vials of powder, 4 ampoules of solvent, 4 injection syringes, 8 injection needles and 4 cleansing swabs)
EU/1/00/131/013 (4 bočice s praškom, 4 ampule s otapalom) EU/1/00/131/014 (4 bočice s praškom, 4 ampule s otapalom, 4 štrcaljke za injekciju, 8 igala za injekciju i 4 tupfera za čišćenje)
PegIntron 120 micrograms powder and solvent for solution for injection Each vial contains 120 micrograms of peginterferon alfa-2b measured on a protein basis.
PegIntron 120 mikrograma prašak i otapalo za otopinu za injekciju Jedna bočica sadrži 120 mikrograma peginterferona alfa-2b, mjereno na bazi proteina.
PegIntron 100 micrograms powder and solvent for solution for injection Each vial is to be reconstituted with 0.7 ml of water for injections for administration of up to 0.5 ml of solution.
PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju Svaka bočica mora se rekonstituirati sa 0,7 ml vode za injekcije za primjenu najviše 0,5 ml otopine.
PegIntron 150 micrograms powder for injection peginterferon alfa-2b
PegIntron 150 mikrograma prašak za injekciju peginterferon alfa-2b s.c.
EU/1/00/131/005 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/026 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/005 (6 bočica s praškom, 6 ampula s otapalom) EU/1/00/131/026 (12 bočica s praškom, 12 ampula s otapalom, 12 štrcaljki za injekciju, 24 igle za injekciju i 12 tupfera za čišćenje)
PegIntron 50 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen (CLEARCLICK) is reconstituted with the solvent provided in the two-chamber cartridge (water for injections) for administration of up to 0.5 ml of solution.
PegIntron 50 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Svaka napunjena brizgalica (CLEARCLICK) rekonstituira se s otapalom (voda za injekcije) koje se nalazi u ulošku s dvije komore, za primjenu najviše 0,5 ml otopine.
EU/1/00/131/031 (1 pen, 1 injection needle and 2 cleansing swabs) EU/1/00/131/032 (4 pens, 4 injection needles and 8 cleansing swabs) EU/1/00/131/034 (12 pens, 12 injection needles and 24 cleansing swabs)
EU/1/00/131/031 (1 brizgalica, 1 igla za injekciju i 2 tupfera za čišćenje) EU/1/00/131/032 (4 brizgalice, 4 igle za injekciju i 8 tupfera za čišćenje) EU/1/00/131/034 (12 brizgalica, 12 igala za injekciju i 24 tupfera za čišćenje)
PegIntron 50 micrograms powder and solvent for solution for injection in pre-filled pen PegIntron 80 micrograms powder and solvent for solution for injection in pre-filled pen PegIntron 100 micrograms powder and solvent for solution for injection in pre-filled pen PegIntron 120 micrograms powder and solvent for solution for injection in pre-filled pen PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen
PegIntron 50 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici PegIntron 80 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici PegIntron 120 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici PegIntron 150 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
EU/1/00/131/010 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/027 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/010 (6 bočica s praškom, 6 ampula s otapalom) EU/1/00/131/027 (12 bočica s praškom, 12 ampula s otapalom, 12 štrcaljki za injekciju, 24 igle za injekciju i 12 tupfera za čišćenje)
EU/1/00/131/015 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/028 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/015 (6 bočica s praškom, 6 ampula s otapalom) EU/1/00/131/028 (12 bočica s praškom, 12 ampula s otapalom, 12 štrcaljki za injekciju, 24 igle za injekciju i 12 tupfera za čišćenje)
PegIntron 80 micrograms powder and solvent for injection peginterferon alfa-2b
PegIntron 80 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
EU/1/00/131/025 (6 vials of powder, 6 ampoules of solvent) EU/1/00/131/030 (12 vials of powder, 12 ampoules of solvent, 12 injection syringes, 24 injection needles and 12 cleansing swabs)
EU/1/00/131/025 (6 bočica s praškom, 6 ampula s otapalom) EU/1/00/131/030 (12 bočica s praškom, 12 ampula s otapalom, 12 štrcaljki za injekciju, 24 igle za injekciju i 12 tupfera za čišćenje)
PegIntron 120 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
PegIntron 120 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici peginterferon alfa-2b
PegIntron 50 micrograms powder and solvent for injection peginterferon alfa-2b
PegIntron 50 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
PegIntron 150 micrograms powder and solvent for injection peginterferon alfa-2b
PegIntron 150 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
PegIntron 120 micrograms powder and solvent for injection peginterferon alfa-2b
PegIntron 120 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
PegIntron 80 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
PegIntron 80 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici peginterferon alfa-2b
PegIntron 100 micrograms powder and solvent for injection peginterferon alfa-2b
PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju peginterferon alfa-2b
Prepare the dose by adding water for injection to PegIntron powder just before you intend to inject it and use it immediately.
Pripremite dozu lijeka tako da vodu za injekcije dodate u PegIntron prašak.
PegIntron 100 micrograms powder and solvent for solution for injection in pre-filled pen Each pre-filled pen (CLEARCLICK) is reconstituted with the solvent provided in the two-chamber cartridge (water for injections) for administration of up to 0.5 ml of solution.
PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Svaka napunjena brizgalica (CLEARCLICK) rekonstituira se s otapalom (voda za injekcije) koje se nalazi u ulošku s dvije komore, za primjenu najviše 0,5 ml otopine.
PegIntron 150 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
PegIntron 150 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici peginterferon alfa-2b
PegIntron 50 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
PegIntron 50 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici peginterferon alfa-2b
Each vial provides 150 micrograms/0.5 ml of solution when reconstituted as recommended
Iz jedne bočice dobiva se 150 mikrograma/0,5 ml otopine, kada se pripremi prema uputama.
PegIntron 100 micrograms powder and solvent for solution for injection in pre-filled pen peginterferon alfa-2b
PegIntron 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici peginterferon alfa-2b
NA
IU
Package inserts of thioridazine should be referred to when co-administering with the product (PegIntron)
Potrebno je pročitati uputu o lijeku za tioridazin kada se primjenjuje istodobno s ovim lijekom (PegIntron).
st dose reduction of PegIntron is to 1 µg/kg/week.
Napomena 2: u odraslih bolesnika prvo smanjenje doze lijeka PegIntron je na 1 μg/kg na tjedan.
Both active substances have been available in the European Union (EU) as separate preparations for a number of years.
Obje djelatne tvari dostupne su u Europskoj Uniji (EU) kao zasebni pripravci već niz godina.
Although the effect of Omidria on pain was modest, it was considered clinically important.
Iako je djelovanje lijeka Omidria na bol skromno, smatra se klinički važnim.
The European Commission granted a marketing authorisation valid throughout the European Union for Omidria on 28 July 2015.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Omidria na snazi u Europskoj uniji od 28. srpnja 2015.
Other information about Omidria
Ostale informacije o lijeku Omidria
This makes lens replacement surgery easier.
To olakšava kiruršku zamjenu leće.
With regard to the safety of Omidria, the medicine was generally well tolerated.
S obzirom na sigurnost lijeka Omidria, lijek se općenito dobro podnosi.
What is Omidria and what is it used for?
Što je Omidria i za što se koristi?
This is a summary of the European public assessment report (EPAR) for Omidria.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Omidria.
The lens is the part of the eye that focuses light passing through the pupil and allows clear vision.
Leća je dio oka koji fokusira svjetlo koje prolazi kroz zjenicu i omogućuje bistar vid.
What measures are being taken to ensure the safe and effective use of Omidria?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Omidria?
It is not intended to provide practical advice on how to use Omidria.
Svrha sažetka nije davati praktične savjete o korištenju lijeka Omidria.
In addition, 7% (29 out of 403) of patients receiving Omidria experienced moderate-to-severe pain compared with 14% (57 out of 403) of patients given placebo, and 25% (104 out of 403) were painfree in the early period following surgery, compared with 17% (69 out of 403) of patients receiving placebo.
Nadalje, 7 % (29 od 403) bolesnika koji su primali lijek Omidria iskusilo je umjerenu do ozbiljnu bol u usporedbi s 14 % (57 od 403) bolesnika koji su primali placebo, te 25 % (104 od 403) nije osjetilo nikakvu bol u ranom razdoblju nakon kirurškog zahvata, u usporedbi sa 17 % (69 od 403) bolesnika koji su primili placebo.
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID).
Ketorolac je nesteroidan protuupalni lijek (NSAID).
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Omidria are greater than its risks and recommended that it be approved for use in the EU.
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Omidria nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
Phenylephrine is a ‘selective alpha-1 adrenergic receptor agonist', which attaches to and activates alpha-1 adrenergic receptors that are found on smooth muscle cells, causing these muscles to contract.
Fenilefrin je "selektivan agonist alfa-1 adrenergičkog receptora" koji se vezuje na i aktivira alfa-1 adrenergičke receptore koji se nalaze na glatkim mišićnim stanicama, uzrokujući kontrakcije mišića.
Why is Omidria approved?
Zašto je Omidria odobren?
This is a type of surgery in which a new lens is implanted into the eye.
Ovo je tip kirurškog zahvata tijekom kojeg se nova leća ugrađuje u oko.
A risk management plan has been developed to ensure that Omidria is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Omidria.
In both studies, the main measures of effectiveness were the change in diameter of the pupil by the end of the surgery, and how much eye pain patients felt soon after surgery, as indicated by the patient using a standard pain scale from 1 to 100.
U oba ispitivanja glavne mjere djelotvornosti bile su promjene u promjeru zjenice po završetku kirurškog zahvata, te koliku je bol bolesnik osjetio u oku odmah nakon kirurškog zahvata, kako je naveo bolesnik koji je koristio standardnu skalu boli od 1 do 100.
Omidria must not be used in patients who have narrow-angle glaucoma, a serious condition of the eye in which the pressure inside the eye rises rapidly because fluid cannot drain out.
Omidria se ne smije koristiti u bolesnika koji imaju glaukom uskog kuta, ozbiljno stanje oka pri kojem se pritisak unutar oka brzo povećava zato što tekućina ne može izaći.
What are the risks associated with Omidria?
Koji su rizici povezani s lijekom Omidria?
When applied to the eye, ketorolac reduces the production of prostaglandins in the eye and thereby reduces the pain and inflammation caused by eye surgery.
Kada se primjenjuje na oko, ketorolac smanjuje proizvodnju prostaglandina u oku i stoga smanjuje bol i upalu koju uzrokuje kirurški zahvat na oku.
The ophthalmologist may also prescribe eye drops commonly used before and after the surgery to help prevent eye infections and pain.
Oftamolog može također propisati kapi za oči koje se najčešće koriste prije i nakon kirurškog zahvata kako bi pomogao u sprječavanju infekcija i boli.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Omidria, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Omidria nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Omidria has been investigated in two main studies involving a total of 821 patients undergoing lens replacement surgery, in which it was compared with placebo (a dummy treatment).
Omidria je ispitana u dva glavna ispitivanja koja su obuhvatila ukupno 821 bolesnika koji su se podvrgavali kirurškoj zamijeni leća, a u kojima je ovaj lijek uspoređen s placebom (lažnim liječenjem).
The most common side effects with Omidria (which may affect up to 1 in 10 people) are eye pain, anterior chamber inflammation (inflammation of the fluid-filled space inside the eye between the iris and the cornea), conjunctival hyperaemia (redness of the membrane that lies over the white part of the eye), photophobia (increased sensitivity of the eyes to light), corneal oedema (swelling of the transparent layer in front of the eye that covers the pupil and iris) and inflammation.
Najčešće nuspojave lijeka Omidria (mogu se javiti u do 1 na 10 bolesnika) su bol u oku, upala prednje komore (upala prostora ispunjenog tekućinom unutar oka između šarenice i rožnice), konjuktivilna hiperemija (crvenilo membrane koja se nalazi preko bijelog dijela oka), fotofobija (povećana osjetljivost oka na svjetlo), edem rožnice (oticanje prozirnog dijela u prednjem dijelu oka koje pokriva zjenicu i šarenicu) i upala.
The recommended dose is 4 ml of Omidria diluted in 500 ml of irrigation solution, to be used during the surgery to replace the lens.
Preporučena doza iznosi 4 ml lijeka Omidria razrijeđen u 500 ml otopine za ispiranje koja se koristi tijekom kirurškog zahvata za zamjenu leća.
It can only be obtained with a prescription and must be given by a qualified ophthalmological surgeon (eye surgery specialist) experienced in lens replacement.
Izdaje se samo na liječnički recept i smije se primjenjivati samo od strane oftalmološkog kirurga (specijalista za očnu kirurgiju) iskusnog u zamijeni leće.
Omidria phenylephrine / ketorolac
Omidria fenilefrin / ketorolak
With respect to pain, patients treated with Omidria reported an average pain score of around 4, compared with around 9 for those given placebo.
Kad je u pitanju doživljaj boli, bolesnici koji su liječeni lijekom Omidria prijavili su prosječan rezultat boli od otprilike 4, u usporedbi s otprilike 9 za osobe koje su primale placebo.
The incidence of side effects with Omidria was similar to that reported in patients receiving placebo.
Incidencija nuspojava s lijekom Omidria slična je onoj prijavljenoj u bolesnika koji su primili placebo.
Both studies showed that the pupil remained dilated during surgery in patients given Omidria (+0.1 mm), while it contracted in those given placebo (-0.5 mm).
Oba su ispitivanja pokazala da je rožnica ostala raširena tijekom kirurškog zahvata u bolesnika koji je primio lijek Omidria (+0,1 mm), dok se zjenica kontrahirala u osoba koje su primile placebo (-0,5 mm).
It works by blocking certain enzymes called cyclo-oxygenases, which produce prostaglandins, substances that are involved in pain and inflammation processes.
Djeluje inhibirajući enzim naziva ciklooksigenaza, koji proizvodi prostaglandine, tvari uključene u bolne i upalne procese.
Omidria is a medicine used in adults during lens replacement surgery in the eye to keep the pupil dilated (widened) and prevent its contraction, and to reduce eye pain after surgery.
Omidria je lijek koji se primjenjuje u odraslih osoba tijekom kirurške zamijene leće oka kako bi se zjenica zadržala dilatiranom (raširenom) te se spriječile kontrakcije zjenice i smanjila bol u oku nakon kirurškog zahvata.
These side effects are typical following lens replacement surgery, and most were mild to moderate in severity and resolved spontaneously.
Ove nuspojave su tipične nakon kirurške zamijene leće, a većina je blaga do umjerena po stupnju ozbiljnosti te se spontano uklanja.
Fewer than 1 in 10 of the patients given Omidria had a pupil diameter below 6 mm (which makes surgery more difficult), whereas about 4 patients in 10 experienced this after being given placebo.
Manje od 1 na 10 bolesnika koji su primili lijek Omidria imalo je promjer zjenice manji od 6 mm (što otežava kirurški zahvat), dok je otprilike 4 bolesnika na 10 iskusilo isto nakon što su primili placebo.
Omidria is available as a concentrate that is made up into an irrigation solution (a solution used to rinse the inside of the eye during surgery).
Omidria je dostupna kao koncentrat za pripremu otopine za ispiranje (otopine koja se koristi za ispiranje unutrašnjosti oka tijekom kirurškog zahvata).
For practical information about using Omidria, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o korištenju lijeka Omidria pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
The full EPAR and risk management plan summary for Omidria can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR za Omidria kao i sažetak plana upravljanja rizikom za lijek Omidria nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Omidria pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
Omidria has been shown to be effective at maintaining pupil dilation and preventing pupil contraction during lens replacement surgery, which should help to make such surgery easier and safer.
Dokazano je da je lijek Omidria djelotvoran u održavanju zjenice raširenom te da sprječava kontrakciju zjenice tijekom kirurške zamjene leće, što pomaže pri olakšavanju takvog kirurškog zahvata i čini ga sigurnijim.
How does Omidria work?
Kako djeluje Omidria?